Iqvia
Ticker: IQV
Company summary: Formerly IMS Health and Quintiles, IQVIA is now a multinational company that conducts contracted clinical research and provides health information technologies.
Market cap: $26.4 billion
Biomarin Pharmaceutical
Ticker: BMRN
Company summary: BioMarin focuses on developing treatments for rare diseases. It recently launched Palynziq, which treats adult phenylketonuria, a rare inherited disorder in which the body can't process an amino acid called phenylalanine. Its pipeline also includes vosoritide (treats achondroplasia, a type of short-limbed dwarfism), val-rox (hemophilia A gene therapy), and BMN250 (treats Sanfilippo Syndrome B).
Market cap: $17.6 billion
Seattle Genetics
Ticker: SGEN
Company summary: Seattle Genetics is a biotech company that develops treatments for cancer. Its lead product is Adcetris, which treats different forms of blood and lymphatic cancers.
Market cap: $12.9 billion
DaVita
Ticker: DVA
Company summary: DaVita is a dialysis clinic operator that services patients with chronic kidney failure and late stage renal disease.
Market cap: $12.4 billion
Universal Health Services
Ticker: UHS
Company summary: Universal Health Services owns and operates acute care hospitals, outpatient facilities, and behavioral healthcare facilities.
Market cap: $11.7 billion
Dexcom
Ticker: DXCM
Company summary: Dexcom makes and sells glucose monitoring devices for diabetic patients.
Market cap: $11.5 billion
Neurocrine Biosciences
Ticker: NBIX
Company summary: Neurocrine Biosciences makes pharmaceutical products for neurological and endocrine-related diseases and disorders.
Market cap: $10.8 billion
Perrigo
Ticker: PRGO
Company summary: Perrigo mainly manufactures over-the-counter medications.
Market cap: $9.8 billion
Nektar Therapeutics
Ticker: NKTR
Company summary: Nektar is a pharmaceutical company that creates drugs to treat cancer, chronic pain and auto-immune disease.
Market cap: $9.5 billion
Sarepta Therapeutics
Ticker: SRPT
Company summary: Sarepta Therapeutics focuses on developing treatments for rare neuromuscular diseases. Its lead product is Exondys, which treats Duchenne muscular dystrophy.
Market cap: $9.5 billion
